SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Apr 10, 2012-- Regulatory News: MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, announced today it will demonstrate its Lesion Management Solutions -LMS- clinical application portfolio together with Canon at ITEM, April 13-15, 2012 in Yokohama, Japan.
This joint presentation results from the strategic partnership agreement signed between Canon Inc and MEDIAN Technologies in July, 2011, with three major objectives: -- To develop new Computer-Aided Diagnosis/Detection (CAD) products and services, -- To make these innovative solutions available to hospitals and biopharmaceutical companies through a cloud-based Software as a Service (SaaS) offering, -- To establish major clinical partnerships in Japan and Asia in particular to validate new imaging solutions developed through the partnership.
"We have been working very closely with CANON Inc. since the signature of our long-term partnership", said Gerard Milhiet, MEDIAN Executive Vice President and co-founder."We are thrilled to support CANON in exploring new opportunities in the region by leveraging existing LMS applications as well as upcoming co-developed LMS solutions in the context of oncology clinical routine and clinical trials, healthcare IT solutions, and lung cancer screening".
The International Technical Exhibition of Medical Imaging (ITEM) is an academic exhibition organized as a part of JRC 2012 by the Japan Industries Association of Radiological Systems (JIRA). This annual exhibition covers a wide range of medical diagnostic imaging devices with related appliances.
About LMS (Lesion Management Solutions) MEDIAN Lesion Management Solutions detect, evaluate and follow-up lesions identified in computed tomography (CT) scans. The LMS perform a number of measurements automatically (such as lesion dimensions, volume and density); these parameters are used in both routine clinical practice and during clinical trials to evaluate patient responses to cancer therapies.
LMS are adaptable and compatible with all CT scanners. They can be integrated into heterogeneous IT environments and easily installed on sites with very diverse equipment and software configurations. MEDIAN LMS are provided as "Software as A Service"; they are web-based, fully distributed and available anywhere in the world.
About MEDIAN Technologies MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon, for the development of new technologies, and with Quintiles, to offer integrated imaging services for clinical trials to customers worldwide.
Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gerard Milhiet, and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a US-based subsidiary.
For more information about MEDIAN, visit www.mediantechnologies.com.
CONTACT: MEDIAN Technologies Fredrik Brag, CEO, +33 4 92 90 65 82 email@example.com or Press - ALIZE RP Caroline Carmagnol + 33 6 64 18 99 59 / + 33 1 42 68 86 43 firstname.lastname@example.org or Anne-Sophie Cosqueric, + 33 1 42 68 86 41 Anneemail@example.com KEYWORD: EUROPE FRANCE INDUSTRY KEYWORD: SOURCE: MEDIAN Technologies Copyright Business Wire 2012 PUB: 04/10/2012 01:30 AM/DISC: 04/10/2012 01:30 AM http://www.businesswire.com/news/home/20120409005139/